On March 10, 2021 — Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, reported that four abstracts highlighting the Company’s lead program, tebentafusp, were accepted at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2021 Annual Meeting, which will be held virtually from April 10-15, 2021 (Press release, Immunocore, MAR 10, 2021, View Source [SID1234576524]). Two abstracts will be presented as oral presentations including, in the plenary session, Phase 3 data comparing tebentafusp (IMCgp100) with investigator’s choice in first line metastatic uveal melanoma (mUM). A second oral presentation will feature data on the kinetics of radiographic response for tebentafusp in previously treated mUM patients. Two abstracts will be poster presentations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PLENARY AND ORAL PRESENTATIONS
Title: Phase 3 randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma
Date and Time: Plenary session presentation (CT002), Saturday April 10th at 11:30am – 1:30pm ET
Presenter: Jessica C. Hassel (PI), University Hospital Heidelberg, Heidelberg, Germany
Abstract #: 5342
Session Title: Phase III Clinical Trials
Title: Kinetics of radiographic response for tebentafusp (tebe) in previously treated metastatic uveal melanoma (mUM) patients (pts) achieving prolonged survival
Date and Time: Oral presentation (CT038), Monday April 12th at 1:30pm – 3:15pm ET
Presenter: Marcus O. Butler (PI), Princess Margaret Cancer Centre, Toronto, ON, Canada
Abstract #: 5338
Session Title: Disease-Oriented Innovative Clinical Research and Trials
POSTER PRESENTATIONS
Title: Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp
Poster #: 1673
Presenter: Jessica Hassel (PI)
Title: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells
Poster #: 517
Presenter: Marcus O. Butler (PI)
Presentations and posters will be available for registered attendees for on-demand viewing on the AACR (Free AACR Whitepaper) website beginning on April 10th 2021.